Skip to main content

Aeterna Zentaris(AEZS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.01
Day High2.19
Open:2.05
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
GlobeNewswire
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
GlobeNewswire
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
GlobeNewswire
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
GlobeNewswire
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
GlobeNewswire
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
GlobeNewswire
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
GlobeNewswire
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
GlobeNewswire
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
GlobeNewswire
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
GlobeNewswire
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

Profile

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.